Heterologous Prime-Boost Clinical study of using INO-4800 and CoronaVac
Latest Information Update: 03 Nov 2022
At a glance
- Drugs INO 4800 (Primary) ; SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Advaccine (Suzhou) Biopharmaceuticals
- 27 Oct 2022 According to an Inovio Pharmaceuticals media release, Advaccine is currently analyzing the data from this heterologous boost trial with INO-4800 and Any future updates on this trial will be provided by Advaccine.
- 17 Aug 2021 New trial record
- 09 Aug 2021 According to an Inovio Pharmaceuticals media release, the company expect to initiate this trial this fall.